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treatment regimens. The impact of patient proﬁle (deﬁned in terms of historical and 
pre-ITI titre levels, age at ITI, age at diagnosis of inhibitors) and FVIII dosage regimen 
on success rates and duration of ITI were estimated via simulation and competing risk 
survival models using data from 113 patients enrolled in two large ITI registries. 
RESULTS: A typical patient initiating ITI with a FVIII dosage of 50–199 IU/Kg/day 
has an estimated 70% success rate. The median time to ITI completion was estimated 
at 15 months. The FVIII-related costs (discounted at 3%) were $1,101,250. The main 
cost driver was the FVIII dosage. For instance, ITI costs ranged from $227,650 for a 
58% success probability with a low-dose (50 IU/kg/day) FVIII dosage regimen to 
$3,281,000 for a 78% success probability on a high-dose (q200 IU/kg/day) regimen. 
Inhibitor titre levels at ITI initiation and historical peak inhibitor levels also impact 
ITI costs, but to a lesser degree than ITI dosage. For instance, patients with historical 
peak titres 50% higher than average incur 10% to 18% higher ITI costs, depending 
on dosage. However, titre levels were predicted to impact success rates to a degree 
comparable to that of dosage. CONCLUSIONS: ITI costs and success rates are driven 
in part by the FVIII dosage and the patient’s risk proﬁle. Ensuring that patients initiate 
ITI with the best possible proﬁle and on the most appropriate regimen has important 
implications in terms of costs and clinical outcomes.
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OBJECTIVES: To estimate the cost of treating patients with haemophilia and inhibi-
tors in Morocco. METHODS: A systematic literature research was performed to 
identify data on the epidemiology and cost of haemophilia. In order to collect informa-
tion about the characteristics of patients, treatment options available and prescribed, 
and the use of health care resources, a structured questionnaire was developed and 
sent to Moroccan key opinion leaders in haemophilia. Data were collected from the 
completed questionnaires and validated in a consensus meeting. A decision analytic 
model was developed to estimate the average direct medical costs per patient per year 
from the Moroccan NHS perspective. A sensitivity analysis was conducted, also con-
sidering values from the literature about other countries. RESULTS: Information 
about the characteristics and the management of Moroccan patients with haemophilia 
and inhibitors is scarce in the literature. Parameters from international literature and 
also values reported by the experts show a wide range in key variables, like patients’ 
weight, number of bleeding episodes, distribution of mild/moderate or severe patients 
and number of severe episodes. Estimated annual total costs were on average 
1,754,635MAD (a159,145) per patient. After completing the sensitivity analysis, it 
was estimated that the average cost per patient could vary from 438,658 DHM 
(a39,786) to 2,485,734 (a225,456). CONCLUSIONS: It is challenging to complete a 
cost study in a country where there are limited sources of local medical information, 
and especially in a low prevalence disease such as haemophilia. As experts see limited 
number of patients with inhibitors, there is a high level of uncertainty about the 
patients’ characteristics, their management and therefore the key variables that drive 
costs. Despite the wide range in the cost estimates, this type of cost studies contribute 
to the better understanding of the disease and provide useful information for decisions 
related to the allocation of resources.
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OBJECTIVES: More than 12% of adult population in Poland (4 million people) are 
obese (BMI  30), with approximately 400 thousand being extremely obese (BMI  
40). In Western Europe up to 4% of total expenditures on health are spent on manag-
ing obesity and obesity dependent chronic diseases including diabetes, cardiovascular 
diseases and cancer. The aim of this study was to estimate direct cost of managing 
obesity in Poland. METHODS: Direct costs of obesity treatment were measured from 
both public payer’s (National Health Fund, NHF) and patients perspective. Data 
regarding standard obesity care were prospectively collected in a population of 72 
obese patients, treated in National Food and Nutrition Institute in Warsaw. Data 
regarding bariatric surgery were provided by experts. Cost data were calculated based 
either on NHF data (public payer perspective) or current market prices (patients per-
spective). Values are presented in Euro (exchange rate: 1 Euro  4,50 PLN). RESULTS: 
We estimate annual cost of obesity care at 325 Euro per patient. with more than 63% 
representing direct medical costs. Based on number and sort of bariatric surgery per-
formed in 2008 in Poland we estimate total cost of surgical treatment for more than 
a2.2 mln (all covered by public payer). Based on NHF data, we estimate less than 30 
thousand obese patients being covered with specialized medical care. Given that, total 
annual cost of obesity treatment in Poland would be as low as a12 mln, representing 
about 0,07% of total expenditures on health in 2008. Direct medical cost covered by 
public payer were estimated at 4 mln Euro representing less than 0,05% of NHF 
expenditures in 2008. Approximately two-thirds of obesity therapy costs are covered 
by patients. CONCLUSIONS: Regarding annual cost of managing obesity dependent 
diseases estimated at a550 mln, obesity therapy expenditures seems to be rather low 
in Poland.
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OBJECTIVES: To carry on a costing of the processes involved in ﬁrst line of Non-
Hodgkin’s Lymphoma (NHL) at private hospital en Mexico. METHODS: In order to 
deﬁne resources and procedures to set the direct medical costs of treatment of NHL 
included treatment, following and medical support; a retrospective review of medical 
histories of a private hospital en Mexico. The revision of the clinical ﬁles include 
patients treated between the fourth quarterly of 2000 and the fourth quarterly of 2006. 
A total of 106 patients were selected but only in 44 cases treatment’s response were 
reported and therefore considered for costing the disease. RESULTS: A total of 44 
patients full ﬁll the inclusion criteria, with a mean age of 55 years (12 to 85); Male 
57% (25) and Female 43% (19); and a Karnofsky of 100% 8 cases, of 90% 6 cases, 
of 80% 7 cases, 40% 1 case and Unknown 22 cases; the initial symptomatology 
(numbers of cases) were Fever: 20; Diaphoreses: 13; weight lost 10% body weight 
in the last 3 months: 25; The Treatment received as a ﬁrst line treatment: Chemo-
therapy 41 and chemotherapy plus radiotherapy 3 with a mean of 2.7 (1–12) cycles. 
The response to the ﬁrst line of treatment (numbers of cases) was: Partial response: 
3, Progression: 19, Death: 15 and Unknown: 7. Costs of Chemotherapy drugs and its 
application US$4,057.07 ($2,337.04–$5,777.09), hematological support US$990.97 
($333.83–$1,648.12), studies and laboratories US$1,383.38 ($712.23–$2,054.52), 
adverse events US$5,125.59 ($1,980.12–$8,271.06), radiotherapy US$84.74 ($0.00–
$183.27). Total cost US$11,641.76 ($6,539.30–$16,744.21). CONCLUSIONS: The 
Costs related to Chemotherapy drugs, its application and the presence of adverse 
events do the chemotherapy represents almost 79% of the total cost of ﬁrst line treat-
ment of Non-Hodgkin’s Lymphoma, which diminishes the importance of having 
alternatives that offer a security proﬁle in order to achieve a more efﬁcient use of the 
available resources.
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OBJECTIVES: To assess the cost-consequences of chronic Neuropathic Pain (NeP) 
outpatients care comparing management in General Clinics (GC) versus Specialized 
Pain Clinics (SPC) in Neurology settings in Spain. METHODS: A 6-month retrospec-
tive observational non interventional study was designed. Adults, both genders 
patients with chronic NeP were included in the analysis. Patients were allocated to 
two type of health care model according to usual administrative procedures in each 
participant centre without investigator participation, consecutively and independently 
of the diagnosis and clinical status of patients. Sociodemographics and clinical char-
acteristics of subjects along with pain-related health care and non health care resources 
utilization were recorded. Work-days missed as a consequence of pain were also col-
lected. Costs were calculated in Euros year 2008 from the societal perspective, while 
severity and interference of pain (BPI scale, range 0–10) were used for effectiveness. 
Patient’s satisfaction with health care was also assessed. RESULTS: A total of 234 
patients (56.8% women, 59.3 o 14.7 years) were included (53.0% in SPCs). Yearly 
indirect cost was a1299 o 2804 in SPC compared to a1483 o 3452 in GC (p  0.660), 
while annual direct costs were, respectively, a2911 o 3335 and a3563 o 4,797 (p  
0.239), with total costs of a4210 o 4654 and a5060 o 6250, respectively (p  0,249). 
Mean pain severity at the time of evaluation was 3.8 o 2.3 in subjects at SPC versus 
5.2 o 2.0 in GC (p  0.0001), while the average interference of pain on daily activities 
were, respectively, 3.3 o 2.0 and 4.7 o 2.5 (p  0.0001). Patients managed at SPC 
were statistically more satisﬁed in all domains of health care satisfaction assessment. 
CONCLUSIONS: . In Neurology settings in Spain, the outpatient clinical management 
of chronic NeP in Specialized Pain Clinics was a dominant alternative compared with 
General Clinics health care, since it was shown better patients health care outcomes 
and satisfaction while maintaining a similar level of costs to the Society.
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OBJECTIVES: The aim of this study is to evaluate the effectiveness of RA treatment 
and the economic impact of the use of methoxypolyethylengycol-epoietin beta (a 
continuous erythropoietin receptor activator, C.E.R.A.) compared with recombinant 
human erythropoietin (EPO-alpha). METHODS: A cost-effectiveness analysis was 
done on the base of a decision tree model that simulates the treatment costs. A 
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systematic review of randomized-comparative clinical trials was performed to deter-
mine the effects and risks associated with the degree of hemoglobin/hematocrit (Hgb/
Hct) level variability outside the recommended range. Diagnostic algorithm and guides 
treatment adaptation were built out of a panel of experts. Resource use and costs data 
were obtained from the Instituto Mexicano del Seguro Social (IMSS). The costs and 
effectiveness were discounted annually at 3%. The threshold to deﬁne a therapy as 
cost-effective was ﬁxed at USD$25,020.00 (least than three times Mexican GDP per 
capita) following the recommendations of WHO’s Commission on Macroeconomics 
and Health. RESULTS: The clinical success rate (patients within 11–12.5 Hbg/dl 
levels) when using C.E.R.A. vs EPO-alpha showed signiﬁcant difference (86.79% 
[95% CI, 84.70%–88.88%] vs 50.48% [95% CI, 47.38%–53.58%] respectively, 
p  0.0001). The treatment care cost per year for C.E.R.A. was US$2,776.13 
(95%CI,US$2,740.9–US$2,811.43) vs US$2,907.88 (95%CI,US$2,883.27–US$2,932.47) 
for EPO-Beta, (p  0.0001); and the hospitalization cost USD$7,089.74 vs 
US$11,255.09 for each one. C.E.R.A. therapy reduces the cost of RA treatment in 
CKD at a 4.53% compared to EPO-alpha therapy and reduced in 37% the hospital 
stay due to Hgb/Hct levels variation. The Cost-effectiveness plane indicates that 
C.E.R.A. is a highly cost-effective therapy; with a probability of 0.60 to be cost saving 
and 0.99 of probability of being cost effective at a USD$4,450 threshold (less than 
one Mexican PIB per capita). CONCLUSIONS: This results show that the use of 
C.E.R.A. for the treatment of RA in patients with CKD is cost-effective.
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OBJECTIVES: The addition of rituximab to cyclophosphamide, vincristine and pred-   
nisolone (R-CVP) signiﬁcantly improved time-to-progression by 17 months in patients         
with previously untreated advanced follicular lymphoma (Marcus et al, 2008). Based      
on these results, we evaluated the clinical outcomes and cost-effectiveness of R-CVP 
versus CVP alone from the perspective of the Romanian National Health Insurance 
House and Ministry of Health. METHODS: A Markov model with a 10-year time 
horizon was developed based on the randomized controlled trial reported by Marcus 
et al. (2008). Rates of disease progression were derived from the PFS Kaplan-Meier 
curves, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group 
database and Romanian age-speciﬁc mortality tables. The duration of the treatment 
effect of rituximab was conservatively applied for the period of clinical trial follow-up 
(90 months) (hazard ratio  0.468). Direct costs included: drug acquisition costs 
(maximum price from Romanian drugs list 2008), hospitalization costs taken from 
NSPHHSM and NHIH (2008) and calculated based on the tariff per chemotherapy 
administration episode, and post-treatment surveillance costs. Costs were discounted 
by 6.0% p.a. RESULTS: This analysis showed that for each FL treatment where R-
CVP is used instead of CVP, the average beneﬁt to the patient would be an additional 
0.983 life years gained (LYG), and 0.931 years when quality-adjusted (QALY). Drug 
acquisition costs were higher with rituximab, however, this was partially offset by 
lower costs for progression. When R-CVP is compared to CVP alone, the incremental 
cost per LYG or QALY gained was calculated as a7155 and a7557, respectively. 
Sensitivity analyses indicated these results were sensitive to the time horizon (longer 
the time horizon, lower the cost per QALY gained) and that the model was robust. 
CONCLUSIONS: This study conﬁrms the long-term clinical and economic beneﬁts of 
adding rituximab to CVP in patients with FL in Romania.
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OBJECTIVES: The rising incidence of invasive fungal infections (IFI), especially inva-
sive aspergillosis, compromises therapeutic outcomes in haematologic cancer patients 
and in transplant recipients.The aim of our analysis was to determine the cost-
 effectiveness of prophylaxis with posaconazole in comparison with standard azole 
therapy (ﬂuconazole or itraconazole) for risk haematology patients in Czech Republic. 
METHODS: The decision-tree economic model was developed for patients with acute 
myelogenous leukemia (AML). The rates of IFI, IFI-related mortality, overall mortality 
and treatment duration were obtained from randomised controlled trials.The cost of 
drugs and IFI hospitalisation was obtained from panel of experts. The model estimates 
total costs, numbers of IFIs, and life-years gained (LYG) per patient in each prophy-
laxis group. Cost and health effects were discounted at 3%. RESULTS: In comparison 
with ﬂuconazole/itraconazole prophylaxis, posaconazole prophylaxis was associated 
with signiﬁcant reduction in the rates of IFI in AML patients, lower IFI-related deaths 
and increased life years. Accumulated cost to the Czech health care system per patient 
receiving the posaconazole regimen was a2770 compared to a2090 for the ﬂucon-
azole/itraconazole regimen. This results in an incremental cost of a680 per patient. 
Incremental life-years saved were 0.016 per patient. The corresponding incremental 
cost effectiveness ratio (ICER) is a42,122 per LYG. Probabilistic sensitivity analysis 
tested numerous assumptions about the model cost and efﬁcacy parameters and found 
that the results were robust to most changes. CONCLUSIONS: In addition to the 
proven efﬁcacy, posaconazole appeared to be cost-effective relative to ﬂuconazole/itra-
conazole in the prophylaxis of IFIs among patients with AML in the settings of Czech 
Republic health care.
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BACKGROUND: Iron deﬁciency and anaemia is common in patients with chronic          
diseases, e.g. chronic kidney disease (CKD), cancer, inﬂammatory bowel disease (IBD), 
and congestive heart failure (CHF) and in connection with large blood losses. One 
appropriate treatment options is intravenous (IV) iron. In Sweden, the Dental and 
Pharmaceutical Beneﬁts Agency, TLV, decides if a medicine should be included in the 
pharmaceutical beneﬁts scheme. TLV makes decisions regarding new products and 
reviews all pharmaceuticals given reimbursement status before 2002. There are three 
IV iron products in Sweden; Ferinject (ferric carboxymaltose), approved for reimburse-     
ment in 2008, and two products approved before 2002: Venofer (iron sucrose) and 
Cosmofer (iron dextran). OBJECTIVES: To present health economic analyses of 
treatment with intravenous iron compared to relevant treatment options in different 
patient populations, i.e. EPO and IV iron vs. EPO and oral iron in CKD, EPO and 
IV iron vs. EPO without iron in cancer, IV Iron vs. no iron in CHF, and IV iron vs. 
oral iron in post-partum and IBD. METHODS: Incremental costs and effects (ICER) 
of IV iron therapy are estimated by comparing relevant treatment alternatives in dif-
ferent patient groups. In CKD, cancer and IBD, model simulations are used. In post-
partum and CHF, a piggyback approach is used. RESULTS: In patients with cancer 
and CKD in dialysis, treatment with IV iron and EPO is found to dominate treatment 
with EPO alone. In IBD patients, intolerant to oral iron, a treatment switch to IV iron 
generated a cost per QALY of a32,377. The ICER for post-partum and CHF patients 
given IV iron compared to oral iron is estimated at a22,280 and a13,850, respectively. 
CONCLUSIONS: The ICER of IV iron treatment compared to relevant alternatives 
is modest for IBD, post-partum and CHF patients and IV iron is dominant for patients 
with haematological cancer and CKD.
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OBJECTIVES: To evaluate the effectiveness and economic consequences of 
treating anemia with original erythropoietic agents in patients with chronic kidney 
disease (CKD) on dialysis and not yet on dialysis. METHODS: The study is a cost-
effectiveness and a cost-minimization analysis based on clinical studies derived from 
the systematic literature search covered Medline and the Cochrane Library. To deter-
mine the economic beneﬁt of using recombinant human erythropoietin (rEPO) agents 
in patients with CKD not on dialysis the comparison between rEPO-A and control 
group were conducted. The cost of rEPO-A, haemodialysis sessions, total days of 
hospitalization, the frequency and the cost of treatment of myocardial infarction were 
taken into account. Cost-minimization analysis were conducted among original eryth-
ropoietic agents (rEPO-A, rEPO-B and Darbepoetin-A (DARB) to determine the one 
who provides the most cost savings in treatment of anemia in patients with CKD on 
dialysis and not on dialysis. RESULTS: This pharmocoeconomic study suggests that 
rEPO-A therapy before dialysis may have a beneﬁcial impact on delaying progression 
to dialysis, reducing hospitalization time and the frequency of cardio-vascular com-
plications. The mean cost savings following the use of rEPO-A before dialysis were 
RUR471,834 (a10,782.3 for June 2009) per patient per year in comparison with 
control group. According to pharmacoeconomic evaluation the application of rEPO-A 
for treatment anemia leads to considerable cost savings in patients with CKD not on 
dialysis (RUR43,761(a1000) per patient per year more than DARB) and in patients 
with CKD on dialysis (RUR83,957(a1918.6) per patient per year more than rEPO-B 
and RUR66,769(a1525.8) per patient per year more than DARB). CONCLUSIONS: 
Correction of anemia with rEPO-A may reduce the utilization of health care resources 
and may lead to improved clinical and economic outcomes.
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OBJECTIVES: Intravenous immunoglobulin (IVIG )has demonstrated improvement 
in chronic inﬂammatory demyelinating polyneuropathy (CIDP) patients in placebo    
contolled trials. However, IVIG is also much more expensive than alternative treat-
ments such as corticosteroids. The objective of the paper is to evaluate, from a Cana-
dian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment 
of CIDP. METHODS: A markov model was used to evaluate the expected costs and 
QALYs for over 5 years for two treatments for CIDP 1) IVIG, and 2) corticosteroids. 
Patients in the IVIG treatment arm could respod or not respond respond or not 
